Deep Learning in Pharmacogenomics: From Gene Regulation to Patient Stratification
Kalinin, Alexandr A., Higgins, Gerald A., Reamaroon, Narathip, Soroushmehr, S. M. Reza, Allyn-Feuer, Ari, Dinov, Ivo D., Najarian, Kayvan, Athey, Brian D.
This Perspective provides examples of current and future applications of deep learning in pharmacogenomics, including: (1) identification of novel regulatory variants located in non-coding domains of the genome and their function as applied to pharmacoepigenomics; (2) patient stratification from medical records; and (3) the mechanistic prediction of drug response, targets, and their interactions. Deep learning encapsulates a family of machine learning algorithms that has transformed many important subfields of artificial intelligence (AI) over the last decade, and has demonstrated breakthrough performance improvements on a wide range of tasks in biomedicine. We anticipate that in the future, deep learning will be widely used to predict personalized drug response and optimize medication selection and dosing, using knowledge extracted from large and complex molecular, epidemiological, clinical, and demographic datasets.
Mar-6-2018
- Country:
- North America > United States
- Michigan (0.28)
- California (0.28)
- North America > United States
- Genre:
- Research Report
- New Finding (1.00)
- Experimental Study (1.00)
- Research Report
- Industry:
- Health & Medicine
- Pharmaceuticals & Biotechnology (1.00)
- Health Care Providers & Services (1.00)
- Government Relations & Public Policy (0.93)
- Health Care Technology > Medical Record (0.89)
- Therapeutic Area
- Psychiatry/Psychology (1.00)
- Oncology (1.00)
- Neurology (1.00)
- Cardiology/Vascular Diseases (0.67)
- Government > Regional Government
- North America Government > United States Government > FDA (0.46)
- Health & Medicine
- Technology: